

General information about company	
Scrip code	540679
NSE Symbol	SMSLIFE
MSEI Symbol	NOTLISTED
ISIN*	INE320X01016
Name of company	SMS Lifesciences India Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2022
Date of end of financial year	31-03-2023
Date of board meeting when results were approved	09-08-2022
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	03-08-2022
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	09-08-2022 17:00
End date and time of board meeting	09-08-2022 19:15
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	8045.31	8045.31
	Other income	29.96	29.96
	Total income	8075.27	8075.27
2	Expenses		
(a)	Cost of materials consumed	5092.93	5092.93
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-439.54	-439.54
(d)	Employee benefit expense	830.03	830.03
(e)	Finance costs	118.12	118.12
(f)	Depreciation, depletion and amortisation expense	198.94	198.94
(f)	Other Expenses		
1	Manufacturing Expenses	1324.69	1324.69
2	Other Expenses	347.55	347.55
10			
	Total other expenses	1672.24	1672.24
	Total expenses	7472.72	7472.72

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	602.55	602.55
4	Exceptional items	0	0
5	Total profit before tax	602.55	602.55
7	Tax expense		
8	Current tax	200	200
9	Deferred tax	-8.03	-8.03
10	Total tax expenses	191.97	191.97
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	410.58	410.58
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	410.58	410.58

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]			
1 Amount of items that will not be reclassified to profit and loss			
Total Amount of items that will not be reclassified to profit and loss			
2	Income tax relating to items that will not be reclassified to profit or loss	1.95	1.95
3 Amount of items that will be reclassified to profit and loss			
Total Amount of items that will be reclassified to profit and loss			
4	Income tax relating to items that will be reclassified to profit or loss	-0.57	-0.57
5	Total Other comprehensive income	-1.38	-1.38

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	409.2	409.2
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	302.33	302.33
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	13.58	13.58
	Diluted earnings (loss) per share from continuing operations	13.58	13.58
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	13.58	13.58
	Diluted earnings (loss) per share from continuing and discontinued operations	13.58	13.58
30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)

1. The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 9th August, 2022 and have been approved by the Board of Directors at its meeting held on 9th August, 2022. The statutory auditors of the Company have carried out a limited review of Standalone financial results for the quarter ended 30th June, 2022 and expressed an unmodified opinion thereon.
 2. The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 3. Exceptional amount for the quarter ended 31.03.2022 represents profit on the sale of investments, i.e 10% of its stake in Mahi Drugs Pvt Ltd, a Wholly Owned Subsidiary, and for the year ended 31.03.2022 represents profit on the sale of Investments and non-revenue generating Land and Buildings.
 4. The figures for the quarter ended 31st March, 2022 are balancing figures between audit figures of the full financial year ended 31st March, 2022 and the published year-to-date figures upto the third quarter ended 31st December, 2021.
 5. The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
 6. Figures for the previous period have been reclassified / regrouped wherever necessary to confirm to current period's classification.
- Note – in the “general info” sheet, under the head “declaration of unmodified opinion”, when we are choosing “Declaration of unmodified opinion” & doing validation, the text of the cell is automatically changed to “Not Applicable”, I think this is some technical glitch. Please note that Statutory Auditor has issued an unmodified opinion to the quarterly results.

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2022	01-04-2022
Date of end of reporting period	30-06-2022	30-06-2022
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		

General information about company	
Scrip code	540679
NSE Symbol	SMSLIFE
MSEI Symbol	NOTLISTED
ISIN*	INE320X01016
Name of company	SMS Lifesciences India Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2022
Date of end of financial year	31-03-2023
Date of board meeting when results were approved	09-08-2022
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	03-08-2022
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Bulk Drugs / API's
Start date and time of board meeting	09-08-2022 17:00
End date and time of board meeting	09-08-2022 19:15
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	8227.58	8227.58
	Other income	30.91	30.91
	Total income	8258.49	8258.49
2	Expenses		
(a)	Cost of materials consumed	4857.86	4857.86
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-396.72	-396.72
(d)	Employee benefit expense	1027.4	1027.4
(e)	Finance costs	163.82	163.82
(f)	Depreciation, depletion and amortisation expense	258.7	258.7
(f)	Other Expenses		
1	Manufacturing Expenses	1526.03	1526.03
2	Other Expenses	364.4	364.4
10			
	Total other expenses	1890.43	1890.43
	Total expenses	7801.49	7801.49

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	457	457
4	Exceptional items	0	0
5	Total profit before tax	457	457
7	Tax expense		
8	Current tax	200	200
9	Deferred tax	24.9	24.9
10	Total tax expenses	224.9	224.9
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	232.1	232.1
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	68.76	68.76
21	Total profit (loss) for period	300.86	300.86

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Other comprehensive income [Abstract]			
1 Amount of items that will not be reclassified to profit and loss			
Total Amount of items that will not be reclassified to profit and loss			
2	Income tax relating to items that will not be reclassified to profit or loss	1.54	1.54
3 Amount of items that will be reclassified to profit and loss			
Total Amount of items that will be reclassified to profit and loss			
4	Income tax relating to items that will be reclassified to profit or loss	-0.46	-0.46
5	Total Other comprehensive income	-1.08	-1.08

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2022	01-04-2022
B	Date of end of reporting period	30-06-2022	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	299.78	299.78
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	302.33	302.33
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	9.95	9.95
	Diluted earnings (loss) per share from continuing operations	9.95	9.95
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	9.95	9.95
	Diluted earnings (loss) per share from continuing and discontinued operations	9.95	9.95
30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)

1. The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 9th August, 2022 and have been approved by the Board of Directors at its meeting held on 9th August, 2022. The statutory auditors of the Company have carried out a limited review of Consolidated financial results for the quarter and year ended 31st March, 2022 and expressed an unmodified conclusion thereon.
 2. The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
 3. The Consolidated financial results include the appropriate share in financial results of Mahi Drugs Private Limited a subsidiary and are prepared by applying Ind AS 110- "Consolidated Financial Statements".
 4. Exceptional amount for the quarter ended 31.03.2022 represents profit on the sale of investments, i.e. 10% of its stake in Mahi Drugs Pvt Ltd, a Wholly Owned Subsidiary, and for the year ended 31.03.2022 represents profit on the sale of Investments and non-revenue generating Assets.
 5. With the dilution of the company's stake in Mahi Drugs Pvt Ltd a subsidiary company by sale of shares and issue of further shares by the said subsidiary by way of preferential allotment, the stake of the company in the subsidiary has reduced from 100% to 60.00% as at 30.06.2022.
 6. The figures for the quarter ended 31st March, 2022 are balancing figures between audit figures of the full financial year ended 31st March, 2022 and the published year to date figures upto third quarter ended 31st December, 2021.
 7. The Consolidated entity is engaged in manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
 8. Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.
- Note – in the “general info” sheet, under the head “declaration of unmodified opinion”, when we are choosing “Declaration of unmodified opinion” & doing validation, the text of the cell is automatically changed to “Not Applicable”, I think this is some technical glitch. Please note that Statutory Auditor has issued an unmodified opinion to the quarterly results.

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2022	01-04-2022
Date of end of reporting period	30-06-2022	30-06-2022
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Consolidated	Consolidated
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		